Sellas Life Sciences Group, Inc. SLSN
Sellas Life Sciences Group, Inc. (Nasdaq: SLSN) is an oncology drug developer. Its lead program, Galinpepimut-S (GPS), is in Phase 3 for Acute myeloid leukemia (AML) in maintenance setting after second complete remission. Its next catalyst on record is SLS009: Topline data from Phase 2 trial of SLS009 in newly diagnosed first-line AML expected in Q4 2026. (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: SLS009 — Topline data from Phase 2 trial of SLS009 in newly diagnosed first-line AML expected in Q4 2026. (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Galinpepimut-S (GPS) | Acute myeloid leukemia (AML) | protein/peptide | Phase 3 |
| SLS009 (tambiciclib) | Newly diagnosed, first-line AML | small molecule | Phase 2 |
| SLS009 (tambiciclib) | Relapsed/refractory AML | small molecule | Phase 2 |
Recent results and decisions
- Aug 11, 2026n/a SELLAS obtained promising preclinical results for SLS009 in PDAC and intends to support clinical development at a top-tier academic institution.
SLS009 has demonstrated the ability to act as a single agent in PDAC cells largely resistant to leading RAS inhibitors and synergize with the RAS inhibition mechanism of action.
Filing - May 12, 2026n/a REGAL Phase 3 event count reached 78 as of May 11, 2026; final analysis triggers at 80th event, company remains blinded.
As of May 11, 2026, 78 events have occurred and SELLAS will provide an update and announce when the 80th event has been reached.
Filing - Mar 19, 2026started First patient dosed in 80-patient Phase 2 trial of SLS009 with AZA/VEN in newly diagnosed/early-refractory AML.
After receiving constructive feedback from the FDA, SELLAS dosed the first patient in an 80-patient trial in newly diagnosed AML patients as well as those who become refractory early to AZA/VEN treatment which we established through our extensive transcriptomics, genomics, and proteomics models.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Merck & Co., Inc. MRK
- Astrazeneca PLC AZN
- Bristol Myers Squibb Co BMY
- BeOne Medicines Ltd. ONC
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.